AR124246A1 - Polipéptidos de interleucina-2 mutante dependientes del ph - Google Patents

Polipéptidos de interleucina-2 mutante dependientes del ph

Info

Publication number
AR124246A1
AR124246A1 ARP210103369A ARP210103369A AR124246A1 AR 124246 A1 AR124246 A1 AR 124246A1 AR P210103369 A ARP210103369 A AR P210103369A AR P210103369 A ARP210103369 A AR P210103369A AR 124246 A1 AR124246 A1 AR 124246A1
Authority
AR
Argentina
Prior art keywords
receptor
polypeptides
dependent mutant
binding
immunoconjugates
Prior art date
Application number
ARP210103369A
Other languages
English (en)
Inventor
Lorenzo Deh
Christian Gassner
Sylvia Herter
Thomas Hofer
Ralf Hosse
Adrian Hugenmatter
Christian Klein
Florian Limani
Ekkehard Moessner
Melanie Obba
Bianca Scherer
Pablo Umaa
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR124246A1 publication Critical patent/AR124246A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere en general a polipéptidos de interleucina-2 mutante dependientes del pH que exhiben una unión reducida al receptor de IL-2 a pH neutro y retienen la unión al receptor de IL-2 a pH reducido. Además, la invención se refiere a inmunoconjugados que comprenden dichos polipéptidos de IL-2 mutante dependientes del pH, moléculas de polinucleótidos que codifican los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, y vectores y células huésped que comprenden tales moléculas de polinucleótidos. La invención se refiere además a métodos para producir los polipéptidos de IL-2 mutante dependientes del pH o inmunoconjugados, composiciones farmacéuticas que los comprenden y usos de estos. Reivindicación 1: Un polipéptido de interleucina-2 (IL-2) mutante que comprende una o más sustituciones de aminoácidos, cada una en comparación con una IL-2 de tipo silvestre, preferentemente IL-2 humana de acuerdo con SEQ ID Nº 144, en donde la una o más sustituciones de aminoácidos anulan o reducen la unión al receptor de IL-2, preferentemente al receptor de IL-2 de afinidad intermedia (IL2Rbg), a pH neutro y facilitan la unión al receptor de IL-2, preferentemente al receptor de IL-2 de afinidad intermedia (IL2Rbg), a pH disminuido.
ARP210103369A 2020-12-04 2021-12-03 Polipéptidos de interleucina-2 mutante dependientes del ph AR124246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20211731 2020-12-04

Publications (1)

Publication Number Publication Date
AR124246A1 true AR124246A1 (es) 2023-03-01

Family

ID=73726565

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP210103369A AR124246A1 (es) 2020-12-04 2021-12-03 Polipéptidos de interleucina-2 mutante dependientes del ph
ARP230100988A AR129131A2 (es) 2020-12-04 2023-04-24 POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230100988A AR129131A2 (es) 2020-12-04 2023-04-24 POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH

Country Status (15)

Country Link
US (1) US20240092853A1 (es)
EP (1) EP4255923A2 (es)
JP (1) JP2023551563A (es)
KR (1) KR20230117122A (es)
CN (1) CN116635403A (es)
AR (2) AR124246A1 (es)
AU (1) AU2021393752A1 (es)
CA (1) CA3197740A1 (es)
CO (1) CO2023007108A2 (es)
CR (1) CR20230219A (es)
IL (1) IL303381A (es)
MX (1) MX2023006480A (es)
PE (1) PE20232045A1 (es)
TW (1) TW202237632A (es)
WO (1) WO2022117692A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
NZ517906A (en) 1999-10-04 2003-01-31 Medicago Inc Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2002355955A1 (en) 2001-08-13 2003-03-03 University Of Southern California Interleukin-2 mutants with reduced toxicity
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP2016098B1 (en) 2006-05-08 2016-09-07 Philogen S.p.A. Antibody-targeted cytokines for therapy
PL2066796T3 (pl) 2006-09-20 2011-11-30 Mt Biomethan Gmbh Sposób i urządzenie do separacji metanu i dwutlenku węgla z biogazu
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
WO2011020783A2 (en) 2009-08-17 2011-02-24 Roche Glycart Ag Targeted immunoconjugates
UA117294C2 (uk) 2011-02-10 2018-07-10 Рош Глікарт Аг Імунокон'югат
SI3102595T1 (sl) * 2014-02-06 2019-02-28 F. Hoffmann-La Roche Ag Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
RS63663B1 (sr) * 2017-04-03 2022-11-30 Hoffmann La Roche Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15

Also Published As

Publication number Publication date
WO2022117692A2 (en) 2022-06-09
AR129131A2 (es) 2024-07-17
CR20230219A (es) 2023-07-07
CO2023007108A2 (es) 2023-06-30
IL303381A (en) 2023-08-01
CA3197740A1 (en) 2022-06-09
TW202237632A (zh) 2022-10-01
JP2023551563A (ja) 2023-12-08
US20240092853A1 (en) 2024-03-21
CN116635403A (zh) 2023-08-22
EP4255923A2 (en) 2023-10-11
WO2022117692A3 (en) 2022-10-20
MX2023006480A (es) 2023-06-19
KR20230117122A (ko) 2023-08-07
PE20232045A1 (es) 2023-12-27
AU2021393752A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
AR129131A2 (es) POLIPÉPTIDOS DE INTERLEUCINA-2 MUTANTE DEPENDIENTES DEL pH
AR126987A2 (es) Inmunoconjugados
JP2019122392A5 (es)
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
NO20055852L (no) Nye peptider som binder til erytropoietinreseptoren
BR0214650A (pt) Imunocitoquinas com seletividade modulada
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
CO6470863A2 (es) Mutantes fgf21 y usos de los mismos
CU23833A3 (es) Anticuerpos antimesotelina
PE20231648A1 (es) CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CO2022014884A2 (es) Inmunoconjugados
BR112022006233A2 (pt) Composições e métodos para síntese in vivo de polipeptídeos não naturais
Burgess et al. Direct evidence for methylation of arginine residues in high molecular weight forms of basic fibroblast growth factor.
KR20110095238A (ko) 인터류킨-15 활성의 펩티드 안타고니스트
MX2022016389A (es) Conjugados de citocina.
BR112022020796A2 (pt) Polipeptídeos de interleucina-22 projetados e usos do mesmos
MX2023003371A (es) Receptores de células t específicos de mage-a3 y su uso.
Karlsson et al. A rapid HPLC method to separate the triplet proteins of neurofilament
MX2024008082A (es) Composiciones que comprenden la preprosecuencia del factor-alfa y sus usos.
CU23504A1 (es) Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
BR0216047A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina diferente de lisina
BR112022003705A2 (pt) Lipase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, composição farmacêutica para o tratamento de insuficiência pancreática, célula hospedeira, métodos para produzir uma lipase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso